Across 107 reviewed trials, breast cancer Phase III eligibility is defined less by diagnosis alone than by treatment sequence, receptor biology, organ-function safeguards, imaging-defined disease state, and reproductive-risk control. The combined 2024–2026 signal points to a highly governed trial-design environment where feasibility pressure comes from layered selectivity rather than any single eligibility domain.
Inclusion criteria clustered most heavily in the 6–10 range, while the combined mean was 10.2 criteria per trial. The observed range was 1–23, showing a meaningful upper tail in biomarker-rich, systemic-treatment, post-neoadjuvant, or treatment-sequencing designs.
The inclusion burden is usually moderate, but complexity rises when eligibility must align tumor subtype, prior therapy, central testing, organ function, reproductive status, and treatment-specific safeguards. This suggests screening design should focus less on diagnosis confirmation alone and more on pre-screening for biology and treatment sequence.
Exclusion criteria were more dispersed than inclusion criteria, with a combined mean of 12.2 and a range of 1–29. The highest burden appears in modern systemic therapy designs involving immunotherapy, ADCs, CDK4/6 inhibition, endocrine switching, HER2-directed therapy, or combination regimens.
Exclusion complexity is a major operational burden because many protocols combine population purification with safety governance. The broad spread suggests feasibility teams should test exclusion impact early, especially where therapy-specific cardiac, infection, organ-function, CNS, or prior-treatment controls accumulate.
The leading exclusion domains show that breast cancer Phase III protocols are primarily controlling treatment history, medical fitness, cardiovascular risk, reproductive risk, and infection or immune vulnerability.
The dominant exclusion signal is treatment-sequence control, followed by safety-risk filtering. This means eligibility feasibility in breast cancer Phase III is likely most sensitive to prior exposure, washout rules, comorbidity handling, and cardiac/infection safeguards—not just receptor subtype.
93.5% of trials used biological, receptor, pathology, or biomarker eligibility. HER2 and ER were the dominant stratifiers, confirming that subtype control is central to Phase III breast cancer trial architecture.
Biomarker eligibility is a core feasibility gate. HER2, ER, PR, pathology confirmation, and selected molecular or immune markers mean that site activation, tissue availability, central testing, assay turnaround, and subtype pre-screening are strategic enrollment variables, not downstream operational details.
Cardiac eligibility was the most prominent organ-function domain at 61.7%, followed by hepatic-function language at 54.2% and renal-function language at 43.9%. Common thresholds included LVEF around ≥50%, bilirubin around ≤1.5×ULN, and CrCl/eGFR around ≥30 mL/min.
Cardiac eligibility is the standout organ-function constraint, consistent with HER2-directed, CDK4/6, endocrine-combination, ADC, and QT-sensitive settings. For feasibility planning, cardiac screening capacity and handling of borderline LVEF/QT findings may be more important than renal thresholds alone.
99.1% of trials used prior-treatment, prohibited-treatment, washout, relapse-timing, or treatment-sequencing criteria. This was the most pervasive eligibility domain in the combined dataset.
Patterns included prior neoadjuvant/adjuvant treatment, endocrine/CDK4/6 exposure, anti-HER2 therapy, recurrence timing, trial participation, washout windows, and no-prior-systemic-therapy rules in selected advanced/metastatic settings.
Prior-treatment logic is effectively the backbone of eligibility. Feasibility assessments should therefore map local patient pathways and prior exposure patterns before site selection, because trial-fit may depend more on therapeutic history than on diagnosis volume.
86.9% of trials used radiological, imaging-linked, staging, measurable-disease, progression, or metastatic-status eligibility. The most decision-useful imaging domains were metastatic/distant disease status, CNS involvement, and measurable or evaluable disease.
Radiology is a central eligibility gate because it defines trial setting: early versus metastatic disease, CNS involvement, measurable disease, progression confirmation, and nodal or distant disease status. Imaging-readiness and RECIST/CNS assessment capability should be treated as feasibility variables.
Reproductive-safety criteria were common but unevenly expressed across the extracted eligibility text. Pregnancy or pregnancy-test language appeared in 61.7%, breastfeeding/lactation exclusions in 43.9%, and contraception requirements in 41.1%.
Reproductive safety remains a recurrent protocol-control domain, especially in systemic therapy contexts. The lower density of explicit language in some records should not be read as absence of risk management; it may reflect where reproductive controls are placed in the protocol or consent package.
Older adults should be considered included by default unless a trial explicitly excludes them or applies an upper-age cap. Explicit upper-age restriction at or below 65 was rare at 2.8%. The more important access issue is likely indirect narrowing through ECOG, cardiac, renal, hepatic, comorbidity, drug-interaction, and prior-treatment criteria.
Age caps are not the main barrier to older-adult access. The practical constraint is indirect: older patients may be screened out through performance status, organ function, cardiac safety, comorbidity, medication interaction, and prior-treatment rules even when the protocol is formally age-permissive.
Prior-treatment logic should be assessed before country and site feasibility, because prior exposure and line-of-therapy rules may define the real eligible pool.
Biomarker and receptor eligibility make tissue access, testing turnaround, and subtype prevalence central to enrollment strategy.
Cardiac restrictions are a major medical-governance lever and may require proactive screening pathways for LVEF, QT, ischemic history, and blood pressure.
Older-adult exclusion is rarely explicit by age cap; practical access is more likely constrained indirectly by functional and safety criteria.
Dataset basis: uploaded CTIS-derived breast cancer Phase III eligibility insight reports for 2024–2026; empty eligibility records were excluded before percentage-based analyses.